US 11,938,172 B2
Method for regulating and controlling GLP-1/GLP-1R and drug
Jinan Li, Guangdong (CN)
Assigned to Talengen International Limited, Hong Kong (CN)
Appl. No. 16/624,170
Filed by Talengen International Limited, Hong Kong (CN)
PCT Filed Jun. 19, 2018, PCT No. PCT/CN2018/091838
§ 371(c)(1), (2) Date Dec. 18, 2019,
PCT Pub. No. WO2018/233604, PCT Pub. Date Dec. 27, 2018.
Claims priority of application No. PCT/CN2017/089067 (WO), filed on Jun. 19, 2017.
Prior Publication US 2020/0206324 A1, Jul. 2, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/48 (2006.01); A61K 45/06 (2006.01); A61P 1/16 (2006.01); A61P 1/18 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 5/48 (2006.01); A61P 5/50 (2006.01); A61P 7/00 (2006.01); A61P 25/00 (2006.01); A61P 25/16 (2006.01)
CPC A61K 38/484 (2013.01) [A61K 45/06 (2013.01); A61P 1/16 (2018.01); A61P 1/18 (2018.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); A61P 5/48 (2018.01); A61P 5/50 (2018.01); A61P 7/00 (2018.01); A61P 25/00 (2018.01); A61P 25/16 (2018.01)] 18 Claims
 
1. A method for treating a disease by regulating GLP-1/GLP-1R, comprising administering an effective amount of plasminogen to a subject, wherein the disease is obesity, osteoporosis, Parkinson's syndrome, lateral sclerosis of the spinal cord, inflammatory bowel disease, dyspepsia, or gastrointestinal ulcer.